JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Junot, C.
Right arrow Articles by Ezan, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Junot, C.
Right arrow Articles by Ezan, E.

Vol. 289, Issue 3, 1257-1261, June 1999

In Vivo Assessment of Captopril Selectivity of Angiotensin I-Converting Enzyme Inhibition: Differential Inhibition of Acetyl-Ser-Asp-Lys-Pro and Angiotensin I Hydrolysis1

Christophe Junot, Joel Menard, Marie-Francoise Gonzales, Annie Michaud, Pierre Corvol and Eric Ezan

Commissariat à l'Energie Atomique, Service de Pharmacologie et d'Immunologie, Saclay, Gif-sur-Yvette, France (C.J., E.E.); Institut National de la Santé et de la Recherche Médicale Unité 367, Paris, France (J.M., M.F.G.); and Institut National de la Santé et de la Recherche Médicale Unité 36, Collège de france, Paris, France (A.M., P.C.)

Angiotensin I-converting enzyme (ACE) is a zinc metallopeptidase that plays a major role in blood pressure regulation. The demonstration that the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a natural and specific substrate of the N-active site of ACE suggests that this enzyme may have a new physiological role such as the modulation of hematopoietic stem cells. In vitro studies have shown that ACE inhibitors displayed various potencies in inhibiting the degradation of different natural or synthetic substrates of ACE, among which captopril inhibits AcSDKP hydrolysis more potently than angiotensin I hydrolysis. To look for this selectivity in vivo, we investigated the pharmacodynamic effect of increasing doses of captopril (0.01-10 mg/kg) during the 90 min after i.v. administration to spontaneously hypertensive rats. Plasma and urinary AcSDKP levels were measured. The renin-angiotensin system was evaluated by measurements of ACE activity in plasma samples, using the synthetic substrate Hip-His-Leu, by determinations of plasma renin concentrations and measurements of arterial blood pressure. The results showed that captopril (0.01-0.3 mg/kg) selectively inhibited AcSDKP hydrolysis, with limited effects on the renin-angiotensin system. AcSDKP levels in plasma and urine rose to a plateau 4 times the basal level for doses more than 0.3 mg/kg. All of the parameters reflecting the renin-angiotensin system were significantly affected at doses of 1 and 10 mg/kg. The present study therefore confirms that captopril can be used to protect hematopoietic stem cells during antitumor chemotherapy while having only a limited effect on cardiovascular homeostasis.

0022-3565/99/2893-1257$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. J. Miller, L. E. Norton, M. P. Murphy, M. C. Dalsing, and J. L. Unthank
The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2523 - H2531.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Krust, R. Vienet, A. Cardona, C. Rougeot, E. Jacotot, C. Callebaut, G. Guichard, J. P. Briand, J. M. Grognet, A. G. Hovanessian, et al.
The anti-HIV pentameric pseudopeptide HB-19 is preferentially taken up in vivo by lymphoid organs where it forms a complex with nucleolin
PNAS, October 31, 2001; (2001) 221467298.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N.-E. Rhaleb, H. Peng, X.-P. Yang, Y.-H. Liu, D. Mehta, E. Ezan, and O. A. Carretero
Long-Term Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Left Ventricular Collagen Deposition in Rats With 2-Kidney, 1-Clip Hypertension
Circulation, June 26, 2001; 103(25): 3136 - 3141.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Junot, M.-F. Gonzales, E. Ezan, J. Cotton, G. Vazeux, A. Michaud, M. Azizi, S. Vassiliou, A. Yiotakis, P. Corvol, et al.
RXP 407, a Selective Inhibitor of the N-Domain of Angiotensin I-Converting Enzyme, Blocks in Vivo the Degradation of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro with No Effect on Angiotensin I Hydrolysis
J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 606 - 611.
[Abstract] [Full Text]

Home page
 HypertensionHome page
H. Peng, O. A. Carretero, L. Raij, F. Yang, A. Kapke, and N.-E. Rhaleb
Antifibrotic Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on the Heart and Kidney in Aldosterone-Salt Hypertensive Rats
Hypertension, February 1, 2001; 37(2): 794 - 800.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Azizi, C. Massien, A. Michaud, and P. Corvol
In Vitro and In Vivo Inhibition of the 2 Active Sites of ACE by Omapatrilat, a Vasopeptidase Inhibitor
Hypertension, June 1, 2000; 35(6): 1226 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Junot, L. Nicolet, E. Ezan, M.-F. Gonzales, J. Menard, and M. Azizi
Effect of Angiotensin-Converting Enzyme Inhibition on Plasma, Urine, and Tissue Concentrations of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro in Rats
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 982 - 987.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Krust, R. Vienet, A. Cardona, C. Rougeot, E. Jacotot, C. Callebaut, G. Guichard, J. P. Briand, J. M. Grognet, A. G. Hovanessian, et al.
The anti-HIV pentameric pseudopeptide HB-19 is preferentially taken up in vivo by lymphoid organs where it forms a complex with nucleolin
PNAS, November 20, 2001; 98(24): 14090 - 14095.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.